Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25173561 | 1.00 | DRD2 (0.50) | DRD2DRD3HTR1ASLC6A3TAAR1 | |
| Hydrochloric Acid SCHEMBL31330702 | 0.99 | DRD2 (0.49) | DRD2DRD3HTR1ASLC6A3TAAR1 | |
| Hydrochloric Acid SCHEMBL34472854 | 0.83 | HTR1A (0.45) | DRD2DRD3HTR1A | |
| SCHEMBL25170238 | 0.82 | SLC6A3 (0.60) | DRD2DRD3HTR1ASLC6A3TAAR1 | |
| SCHEMBL24009800 | 0.82 | SLC6A3 (0.60) | DRD2DRD3HTR1ASLC6A3TAAR1 | |
| SCHEMBL24002227 | 0.82 | SLC6A3 (0.60) | DRD2DRD3HTR1ASLC6A3TAAR1 | |
| SCHEMBL30403441 | 0.82 | SLC6A3 (0.53) | HTR1ASLC6A3TAAR1 | |
| SCHEMBL24002088 | 0.82 | SLC6A3 (0.53) | HTR1ASLC6A3TAAR1 | |
| Hydrochloric Acid SCHEMBL27074343 | 0.81 | SLC6A3 (0.59) | DRD2DRD3HTR1ASLC6A3TAAR1 | |
| SCHEMBL24297735 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885HTR1A 713/4885 |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885HTR1A 713/4885 |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885HTR1A 713/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885HTR1A 713/4885 |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885HTR1A 713/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885HTR1A 713/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885HTR1A 713/4885 |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | DRD2 1052/4885DRD3 2484/4885HTR1A 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.